Current FDA-Approved Therapies for High-Grade Malignant Gliomas
The standard of care (SOC) for high-grade gliomas (HGG) is maximally safe surgical resection, followed by concurrent radiation therapy (RT) and temozolomide (TMZ) for 6 weeks, then adjuvant TMZ for 6 months. Before this SOC was established, glioblastoma (GBM) patients typically lived for less than o...
Main Authors: | Jacob P. Fisher, David C. Adamson |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/9/3/324 |
Similar Items
-
Selected cytostatic drugs in the treatment of brain glioma – literature review
by: Jarosław Bała, et al.
Published: (2021-11-01) -
Novel diagnostic and therapeutic approaches to malignant glioma
by: Swiss Medical Weekly
Published: (2011-05-01) -
Efficacy and safety of innate and adaptive immunotherapy combined with standard of care in high-grade gliomas: a systematic review and meta-analysis
by: Baofeng Guo, et al.
Published: (2023-07-01) -
High costs, low quality of life, reduced survival, and room for improving treatment: an analysis of burden and unmet needs in glioma
by: Johannes Pöhlmann, et al.
Published: (2024-03-01) -
A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults
by: Patrick Roth, et al.
Published: (2020-06-01)